4
Changes in Ownership
Lineage Cell Therapeutics, Inc. Filed Acc 0001209191-16-151321
Options or other derivatives
- Sr VP, Head of Corporate Dev acquired 300,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
KNIGHT JAMES A. · Sr VP, Head of Corporate Dev
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2016-10-19 | Grant or award : show line 1 in the form Option to Purchase Common Shares | +300,000 | $3.49 | 2026-10-18 | 300,000 | 300,000 | D |
Loading xslF345X03/doc4.xml…